D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Oizel, K ^a,b   Gratas, C ^a,b,c   Nadaradjane, A ^a,b   Oliver, L ^a,b,c   Vallette, F M ^a,b,d   Pecqueur, C ^a,b  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UMR INSERM U892 CNRS 6299   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-HYDROXYGLUTARATE; ETOPOSIDE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXOGLUTARATE DEHYDROGENASE;

APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; HUMAN; METABOLISM; MITOCHONDRION; MUTATION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; KETOGLUTARATE DEHYDROGENASE COMPLEX; MITOCHONDRIA; MUTATION; NAD;

EID: 84965089463     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2015.13     Document Type: Article

References (39)

1. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807–1812.
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl JMed2009; 361: 1058–1066.
4. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334–343.
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol (Berl) 2007; 114: 97–109.
6. Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am 2011; 25: 1119–1133.
7. Rakheja D, Konoplev S, Medeiros LJ, Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol 2012; 43: 1541–1551.
8. Pecqueur C, Oliver L, Oizel K, Lalier L, Vallette FM. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol 2013; 2013: 1–13.
9. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.
10. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010; 102: 932–941.
11. Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012; 287: 14615–14620.
12. Oermann EK, Wu J, Guan K-L, Xiong Y. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 2012; 23: 370–380.
13. Chowdhury R, Yeoh KK, Tian Y-M, Hillringhaus L, Bagg EA, Rose NR et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463–469.
14. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17–30.
15. Cartron P-F, Juin P, Oliver L, Martin S, Meflah K, Vallette FM. Nonredundant role of bax and bak in bid-mediated apoptosis. Mol Cell Biol 2003; 23: 4701–4712.
16. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.
17. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479–483.
18. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474–478.
19. Losman J-A, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621–1625.
20. Bralten LBC, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 2011; 69: 455–463.
21. Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan L-J, Gooden DM et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and D-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem 2014; 22: 23318–23328.
22. Kim SY, Yoo YH, Park J-W. Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochem Biophys Res Commun 2013; 433: 260–265.
23. Jung KH, Park J-W. Suppression of mitochondrial NADP(+)-dependent isocitrate dehydrogenase activity enhances curcumin-induced apoptosis in HCT116 cells. Free Radic Res 2011; 45: 431–438.
24. Kil IS, Jung KH, Nam WS, Park J-W. Attenuated mitochondrial NADP+-dependent isocitrate dehydrogenase activity enhances EGCG-induced apoptosis. Biochimie 2011; 93: 1808–1815.
25. Kil IS, Chung KH, Park J-W. Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances selenite-induced apoptosis. Free Radic Res 2010; 44: 332–339.
26. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol 2013; 15: 57–68.
27. Mohrenz IV, Antonietti P, Pusch S, Capper D, Balss J, Voigt S et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 2013; 18: 1416–1425.
28. McKenna MC, Stevenson JH, Huang X, Hopkins IB. Differential distribution of the enzymes glutamate dehydrogenase and aspartate aminotransferase in cortical synaptic mitochondria contributes to metabolic compartmentation in cortical synaptic terminals. Neurochem Int 2000; 37: 229–241.
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891–899.
30. Greenhouse WV, Lehninger AL. Occurrence of the malate-aspartate shuttle in various tumor types. Cancer Res 1976; 36: 1392–1396.
31. Erecińska M, Nelson D. Activation of glutamate dehydrogenase by leucine and its nonmetabolizable analogue in rat brain synaptosomes. J Neurochem 1990; 54: 1335–1343.
32. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008; 10: R84.
33. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011; 108: 3270–3275.
34. Rej R. Measurement of aspartate aminotransferase activity: effects of oxamate. Clin Chem 1979; 25: 555–559.
35. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34: 1514–1521.
36. Kulawiec M, Owens KM, Singh KK. Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther 2009; 8: 1378–1385.
37. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res 2014; 74: 3317–3331.
38. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225–234.
39. Gratas C, Séry Q, Rabé M, Oliver L, Vallette FM. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. Oncotarget 2014; 5: 2428–2435.